Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
-
Narrated by:
-
By:
About this listen
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
(00:32)
Could you give us a brief overview about your background and yourself?
(02:16)
Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?
(05:34)
What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?
(08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?
(10:36)
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?
(13:27)
How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?
(14:02)
Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?